Advertisement

ESMO 2016 Abstract 940TiP - Pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM): randomized, phase 3 KEYNOTE-185 study

The randomized, open-label, phase 3 KEYNOTE-185 study (ClinicalTrials.gov, NCT02579863) was designed to compare the efficacy and safety of lenalidomide and low-dose dexamethasone (standard of care) with or without pembrolizumab in patients with newly diagnosed and treatment-naive MM.

 ESMO

click me